{"filing":{"accession_number":"0001193125-26-349170","cik":"0001404281","ticker":"ELDN","company_name":"Eledon Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"eldn-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1404281/000119312526349170/eldn-20260813.htm"},"events":[{"id":27590,"run_id":25156,"accession_number":"0001193125-26-349170","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses quarterly financial results including R\u0026D expenses ($18.2M), G\u0026A expenses ($4.6M), net loss ($31.6M or $0.27 per share), and cash position ($88.8M), along with business highlights regarding tegoprubart clinical development. The filing explicitly states it is \"furnished to comply with Item 2.02 of Form 8-K\" and includes condensed consolidated financial statements.","company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29180,"accession_number":"0001193125-26-349170","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses quarterly financial results including R\u0026D expenses ($18.2M), G\u0026A expenses ($4.6M), net loss ($31.6M or $0.27 per share), and cash position ($88.8M), along with business highlights regarding tegoprubart clinical development. The filing explicitly states it is \"furnished to comply with Item 2.02 of Form 8-K\" and includes condensed consolidated financial statements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:02:07.138879+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29180,"accession_number":"0001193125-26-349170","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses quarterly financial results including R\u0026D expenses ($18.2M), G\u0026A expenses ($4.6M), net loss ($31.6M or $0.27 per share), and cash position ($88.8M), along with business highlights regarding tegoprubart clinical development. The filing explicitly states it is \"furnished to comply with Item 2.02 of Form 8-K\" and includes condensed consolidated financial statements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:02:07.138879+00:00","company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","filing_date":"2026-08-13"}]}